Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Life Sciences Industry Analysis

UpdatedJun 10, 2026
DataAggregated Company Financials
Companies64
  • 7D3.4%
  • 3M7.0%
  • 1Y10.7%
  • YTD-11.4%

In the last week, the Life Sciences industry is up 3.4%, with Danaher up 7.0%. This takes the industry's 12 month performance to a gain of 11%. Earnings are forecast to grow by 17% annually.

Industry Valuation and Performance

Has the U.S. Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 10 Jun 2026US$584.3bUS$150.6bUS$13.8b40x42.5x3.9x
Fri, 08 May 2026US$555.7bUS$150.2bUS$14.0b33.7x39.7x3.7x
Sun, 05 Apr 2026US$561.9bUS$147.8bUS$14.1b37.2x39.9x3.8x
Tue, 03 Mar 2026US$599.3bUS$147.9bUS$14.0b35.2x42.9x4.1x
Thu, 29 Jan 2026US$694.7bUS$146.1bUS$12.5b35.3x55.7x4.8x
Sat, 27 Dec 2025US$664.7bUS$145.8bUS$12.5b35.4x53.3x4.6x
Mon, 24 Nov 2025US$666.4bUS$145.6bUS$12.4b36.2x53.8x4.6x
Wed, 22 Oct 2025US$635.9bUS$144.3bUS$14.6b33.9x43.7x4.4x
Fri, 19 Sep 2025US$568.9bUS$144.3bUS$14.6b31.3x39.1x3.9x
Sun, 17 Aug 2025US$583.4bUS$144.2bUS$14.5b29x40.3x4x
Tue, 15 Jul 2025US$551.8bUS$142.9bUS$9.1b36.1x60.4x3.9x
Thu, 12 Jun 2025US$536.6bUS$142.9bUS$9.2b36.3x58.5x3.8x
Sat, 10 May 2025US$516.9bUS$142.8bUS$9.6b34.4x53.9x3.6x
Mon, 07 Apr 2025US$509.0bUS$142.5bUS$9.9b33.4x51.2x3.6x
Wed, 05 Mar 2025US$594.9bUS$143.0bUS$9.7b40.5x61.4x4.2x
Fri, 31 Jan 2025US$674.7bUS$143.0bUS$10.4b41.1x65.1x4.7x
Sun, 29 Dec 2024US$657.8bUS$142.4bUS$10.2b44.7x64.3x4.6x
Tue, 26 Nov 2024US$656.3bUS$142.4bUS$10.4b44.4x63.4x4.6x
Thu, 24 Oct 2024US$711.0bUS$142.0bUS$8.3b35.9x85.6x5x
Sat, 21 Sep 2024US$755.8bUS$141.8bUS$8.5b37.7x88.9x5.3x
Mon, 19 Aug 2024US$738.6bUS$141.5bUS$8.4b38.8x88.3x5.2x
Wed, 17 Jul 2024US$683.9bUS$141.2bUS$12.2b41.9x56x4.8x
Fri, 14 Jun 2024US$698.2bUS$141.3bUS$12.2b37.4x57.3x4.9x
Sun, 12 May 2024US$729.1bUS$141.5bUS$12.6b38.6x57.7x5.2x
Tue, 09 Apr 2024US$727.9bUS$142.1bUS$12.8b43.2x56.9x5.1x
Thu, 07 Mar 2024US$744.6bUS$142.1bUS$12.8b44.6x58x5.2x
Sat, 03 Feb 2024US$709.3bUS$147.5bUS$12.5b38.3x56.6x4.8x
Mon, 01 Jan 2024US$700.2bUS$153.8bUS$14.2b37.8x49.2x4.6x
Wed, 29 Nov 2023US$637.7bUS$153.8bUS$14.0b34.5x45.5x4.1x
Fri, 27 Oct 2023US$578.8bUS$154.0bUS$11.0b29.9x52.4x3.8x
Sun, 24 Sep 2023US$670.2bUS$154.6bUS$11.2b33.5x59.8x4.3x
Tue, 22 Aug 2023US$702.8bUS$154.6bUS$11.2b32.9x62.7x4.5x
Thu, 20 Jul 2023US$716.3bUS$155.5bUS$12.7b29.6x56.5x4.6x
Sat, 17 Jun 2023US$704.2bUS$152.4bUS$12.5b29.3x56.3x4.6x
Price to Earnings Ratio

56.3x


Total Market Cap: US$704.2bTotal Earnings: US$12.5bTotal Revenue: US$152.4bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Life Sciences Industry Price to Earnings3Y Average 56.4x202420252026
Current Industry PE
  • Investors are pessimistic on the American Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 42.5x which is lower than its 3-year average PE of 56.4x.
  • The 3-year average PS ratio of 4.4x is higher than the industry's current PS ratio of 3.9x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have grown 3.2% per year over the last three years, while revenues have remained mostly flat.
  • This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market-3.33%
Healthcare5.05%
Life Sciences3.41%
Clinical Research and Equipment3.41%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
DHR DanaherUS$188.417.0%
+US$8.7b		-7.0%PE36.3x
TMO Thermo Fisher ScientificUS$494.072.5%
+US$4.5b		19.2%PE26.8x
WST West Pharmaceutical ServicesUS$334.667.2%
+US$1.6b		47.0%PE43.6x
ICLR ICONUS$151.8210.4%
+US$1.1b		4.9%PE50.7x
IQV IQVIA HoldingsUS$186.253.1%
+US$936.3m		16.6%PE22.4x

Latest News

DHR
US$188.41
Danaher
7D
7.0%
1Y
-7.0%
TEM
US$48.82
Tempus AI
7D
-1.6%
1Y
-29.6%
STVN
US$18.10
Stevanato Group
7D
-3.7%
1Y
-26.5%
LAB
US$0.89
Standard BioTools
7D
-23.6%
1Y
-17.9%
PSNL
US$9.75
Personalis
7D
-12.5%
1Y
76.3%
ABCL
US$5.30
AbCellera Biologics
7D
-13.5%
1Y
75.5%
Seeking Alpha • Jun 09

AbCellera: Q3 Hot Flashes Data Drop Aside, This Stock Is A Difficult Sell

Summary AbCellera Biologics Inc. remains rated Hold, with valuation concerns outweighing near-term pipeline catalysts despite recent share price volatility. ABCL635, targeting hot flashes, is advancing to a Phase 2 trial with a key data readout expected in Q3, potentially derisking the program. Partnered and proprietary pipeline programs lack momentum, with most assets preclinical or awaiting external funding, limiting near-term revenue visibility. Current valuation appears to price in optimistic ABCL635 outcomes, while a trial miss could trigger a 30–50% share price decline. Read the full article on Seeking Alpha
ILMN
US$160.03
Illumina
7D
-1.6%
1Y
81.9%
TMO
US$494.07
Thermo Fisher Scientific
7D
2.5%
1Y
19.2%
Narrative Update • Jun 09

TMO: AI Tools And Proteomics Platforms Will Drive Future Upside

Thermo Fisher Scientific's updated fair value estimate has moved down from about $738 to $721 per share as analysts temper longer term revenue growth assumptions, partly reflecting recent price target cuts and more cautious views on organic growth momentum, even as they acknowledge that the company's margin profile and P/E remain supportive. Analyst Commentary Recent Street research paints a mixed picture for Thermo Fisher Scientific, with some analysts turning more cautious on near term organic growth while others highlight the stock as a core holding for exposure to life science tools.
WST
US$334.66
West Pharmaceutical Services
7D
7.2%
1Y
47.0%
TECH
US$54.41
Bio-Techne
7D
9.3%
1Y
5.9%
ICLR
US$151.82
ICON
7D
10.4%
1Y
4.9%
IQV
US$186.25
IQVIA Holdings
7D
3.1%
1Y
16.6%
BIO
US$297.17
Bio-Rad Laboratories
7D
-2.9%
1Y
28.9%
Narrative Update • Jun 04

BIO: Activist Pressure And Buybacks Will Shape Future Value Realization

Analysts have reaffirmed their $320.00 price target for Bio-Rad Laboratories, citing adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E as the main factors behind the updated view. What's in the News Activist investor Elliott Investment Management has taken a significant stake in Bio-Rad Laboratories after the stock declined more than 70% from its late 2021 peak, and is publicly pushing for improvements in the share price and company performance.
MTD
US$1,162.79
Mettler-Toledo International
7D
-0.6%
1Y
-4.4%
Narrative Update • Jun 03

MTD: Automation And Emerging Markets Will Support EPS Upside Despite Geopolitical Risks

Analysts have trimmed their average price target for Mettler-Toledo International from about $1,344.50 to roughly $1,327.83. This reflects updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E expectations.
CRL
US$189.85
Charles River Laboratories International
7D
8.6%
1Y
25.7%
Narrative Update • Jun 03

CRL: Rich Multiple And Margin Pressure Will Likely Cap AI Upside

Analysts have lifted the fair value estimate for Charles River Laboratories International by about $6.81 per share to $154.56, citing a more supportive regulatory backdrop for cross-border biotech work and expectations that divesting lower margin operations could improve overall earnings quality. Analyst Commentary Recent research commentary on Charles River Laboratories International has leaned more constructive on the regulatory backdrop for cross-border biotech work and on the potential earnings mix shift from divesting lower margin activities.
AVTR
US$9.91
Avantor
7D
10.2%
1Y
-27.6%